指南与共识心脑血管急症儿科与产科急症

委员会意见第692号摘要:妊娠期及产后急性发作严重高血压的紧急治疗

Committee Opinion No. 692 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.
指南 / 共识 · Obstet Gynecol · 2017-01-01
一句话结论妊娠期或产后急性发作严重高血压应在确诊后30-60分钟内启动一线降压治疗以降低孕产妇卒中风险,一线药物包括静脉拉贝洛尔、肼屈嗪或口服即释硝苯地平。

该委员会意见指出,妊娠期、产时或产后出现的急性发作严重收缩压高血压、严重舒张压高血压或两者兼有,均需紧急降压治疗。实施标准化的循证临床指南已被证明可减少不良母体结局。机构和个体应建立机制,在患者出现高血压急症时立即给药。一线药物治疗应尽快在确诊严重高血压后30-60分钟内启动,以降低孕产妇卒中风险。静脉拉贝洛尔和肼屈嗪长期被视为一线药物;现有证据提示口服即释硝苯地平也可考虑作为一线治疗,尤其在无静脉通路时。若连续给予适当剂量的一线药物仍不能缓解,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。

要点

  • 妊娠期或产后急性发作严重高血压需紧急降压,一线治疗应在确诊后30-60分钟内尽快启动,以降低孕产妇卒中风险。
  • 静脉拉贝洛尔和肼屈嗪长期被视为妊娠期及产后急性发作严重高血压的一线药物。
  • 口服即释硝苯地平也可考虑作为一线治疗,尤其在没有静脉通路时。
  • 若连续适当剂量的静脉拉贝洛尔、肼屈嗪或口服即释硝苯地平未能缓解严重高血压,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。
  • 实施标准化的循证临床指南已被证明可减少子痫前期和子痫患者的不良母体结局。

适用人群与场景

  • 妊娠期、产时或产后出现急性发作严重收缩压高血压、严重舒张压高血压或两者的孕妇或产后妇女。

诊断标准与关键阈值

  • 急性发作严重高血压定义为急性发作的严重收缩压高血压、严重舒张压高血压或两者兼有。

处置流程与药物剂量

  • 个体和机构应建立机制,在患者出现高血压急症时立即启动给药。
  • 一线药物治疗应尽快在确诊严重高血压后30-60分钟内启动,以降低孕产妇卒中风险。
  • 静脉拉贝洛尔和肼屈嗪长期被视为妊娠期及产后急性发作严重高血压的一线药物。
  • 口服即释硝苯地平也可考虑作为一线治疗,尤其在没有静脉通路时。
  • 若连续给予适当剂量的静脉拉贝洛尔、肼屈嗪或口服即释硝苯地平仍不能缓解急性发作严重高血压,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。

红旗征与不能漏的情况

  • 妊娠期或产后急性发作严重高血压需紧急降压治疗,应在30-60分钟内启动一线药物以降低孕产妇卒中风险。

研究设计与关键结果

  • 实施标准化的循证临床指南管理子痫前期和子痫患者已被证明可减少不良母体结局的发生率。

证据类型、等级与局限

  • 证据类型:委员会意见(指南/共识)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对妊娠期或产后急性发作严重高血压患者,应在确诊后30-60分钟内尽快启动一线降压治疗,以降低孕产妇卒中风险。
  • 一线药物可选择静脉拉贝洛尔、肼屈嗪;无静脉通路时可考虑口服即释硝苯地平。
  • 连续适当剂量一线药物未能缓解时,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。
  • 机构和个体应建立机制确保高血压急症患者能立即给药。

指南或共识出处

  • 委员会意见第692号摘要:妊娠期及产后急性发作严重高血压的紧急治疗(Obstet Gynecol)。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes. Individuals and institutions should have mechanisms in place to initiate the prompt administration of medication when a patient presents with a hypertensive emergency. Treatment with first-line agents should be expeditious and occur as soon as possible within 30-60 minutes of confirmed severe hypertension to reduce the risk of maternal stroke. Intravenous labetalol and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period. Although relatively less information currently exists for the use of calcium channel blockers for this clinical indication, the available evidence suggests that immediate release oral nifedipine also may be considered as a first-line therapy, particularly when intravenous access is not available. In the rare circumstance that intravenous bolus labetalol, hydralazine, or immediate release oral nifedipine fails to relieve acute-onset, severe hypertension and is given in successive appropriate doses, emergent consultation with an anesthesiologist, maternal-fetal medicine subspecialist, or critical care subspecialist to discuss second-line intervention is recommended.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

参考来源

  1. Committee Opinion No. 692 Summary: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol. 2017. PMID: 28333812. doi:10.1097/AOG.0000000000002010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。